Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2021

View Archived Issues

LY-487379 shows synergistic effect on low-dose L-DOPA in a marmoset model

SB-0107 shows antiparkinsonian activity in animal models

Researchers establish N. gonorrhoeae upper reproductive tract infection model

Perampanel ameliorates development of alpha-syn pathology in models of PD

Japan Tobacco describes new PDHK2 inhibitors

Kallyope presents new free fatty acid FFA1 receptor agonists

Servier discovers nuclear factor erythroid 2-related factor 2 activators

NLRP3 inflammasome inhibitors patented by Cadila Healthcare

Potent inhibitor of sAC shows potential as nonhormonal contraceptive

Ventus outlines NLRP3 inhibitor program

Second Genome collaborates with VCU to generate biomarker for NASH with advanced fibrosis

Discovery of novel EP3 receptor antagonists

Chimeric spike mRNA-LNP vaccines show cross-protection against Sarbecovirus strains in vivo

Improved method of oligonucleotide synthesis using a novel P(V) platform

Avicanna's novel cannabinoid formulation shows promising preclinical results for epilepsy

Neddylation inhibition identified as a means of treating malignant rhabdoid tumors

Boan reports preclinical research data on CEA/CD3 bispecific antibody BA-1202

Infection derails healing after brain injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...